Atlas Trials

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease

Clinical trial NCT06825169 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06825169
Sponsor
Nuwacell Biotechnologies Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Interstitial Lung Disease (ILD)
Start date
2025-03-01
Primary completion
2026-03-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.